Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company’s Board of Directors (the “Board”). Dr. Malloy will also Chair the Board’s Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee.

“We are very excited to welcome Kirk to our Board of Directors,” said Robert Spignesi, President and Chief Executive Officer. “Kirk is an experienced executive and board director with a proven track record of leadership in the life sciences industry. His insights and guidance in commercial expansion at high-growth companies will be invaluable as we continue to grow globally.”

Dr. Malloy has more than 25 years of senior management experience in life sciences and in vitro diagnostics with Illumina, Inc., Biosite, Inc. and Qiagen, Inc., and most recently served as Chief Executive Officer of Verogen, Inc., until its acquisition in 2023. Throughout his career, Dr. Malloy has led market development and product development initiatives that have driven revenue growth for early-stage, commercial companies. Dr. Malloy is currently the founder and principal of BioAdvisors, LLC, where he provides strategic consulting services to life sciences, diagnostics and genomics companies. Currently, Dr. Malloy serves on the boards of NanoString Technologies, Inc. and DermTech, Inc. as well as several private genomics tools companies. Dr. Malloy earned a B.S. in Biology & Marine Science from the University of Miami, and an M.S. and Ph.D. in Marine Biology/Biochemistry from the University of Delaware. He has held post-doctoral and instructor positions at Boston University and Northeastern University.

Mr. Schwartz added, “Kirk is an exceptional leader and my fellow Board members and I are excited to welcome him as our new Board Chair. I look forward to working with Kirk and am confident that, with his deep experience in the life sciences industry, especially with high growth companies, the Company will further capitalize on our significant growth opportunities.”